MedTrace Logo

A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines

NCT01004653 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-03-15

No results posted yet for this study

Summary

A single center, Open-Label phase IV clinical trial is to be conducted in healthy elders (equal to or more than 61 years to evaluate the immunogenicity and safety of Sinovac's 15μg H1N1 influenza A Vaccine (Split virion), Inactivated.

Conditions

Interventions

BIOLOGICAL

H1N1 influenza A Vaccine (Split virion), Inactivated

100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated

Sponsors & Collaborators

  • Sinovac Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2009-10-31
Completion
2009-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01004653 on ClinicalTrials.gov